MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Boston Scientific Corp.

Suletud

SektorTervishoid

88.13 -2.07

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

88.09

Max

88.48

Põhinäitajad

By Trading Economics

Sissetulek

1.4B

2.2B

Müük

4M

5.1B

P/E

Sektori keskmine

51.187

90.831

Aktsiakasum

0.75

Kasumimarginaal

43.87

Töötajad

53,000

EBITDA

-341M

1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+42.82% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-7.1B

142B

Eelmine avamishind

90.2

Eelmine sulgemishind

88.13

Uudiste sentiment

By Acuity

61%

39%

298 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Boston Scientific Corp. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. jaan 2026, 13:29 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15. jaan 2026, 12:35 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15. jaan 2026, 12:29 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

22. okt 2025, 11:00 UTC

Tulu

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

15. jaan 2026, 14:37 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15. jaan 2026, 13:45 UTC

Omandamised, ülevõtmised, äriostud

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15. jaan 2026, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15. jaan 2026, 12:03 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15. jaan 2026, 12:01 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15. jaan 2026, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15. jaan 2026, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

12. jaan 2026, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

12. jaan 2026, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Specific Terms of Valencia Transaction Not Disclosed >BSX

12. jaan 2026, 12:03 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific: Valencia Focused on Development of Solutions to Treat Bladder Dysfunction >BSX

12. jaan 2026, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire Valencia Technologies Corporation >BSX

18. nov 2025, 17:06 UTC

Tulu

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18. nov 2025, 12:01 UTC

Tulu

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

30. okt 2025, 12:38 UTC

Tulu

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

30. okt 2025, 12:01 UTC

Tulu

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

22. okt 2025, 10:32 UTC

Tulu

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22. okt 2025, 10:32 UTC

Tulu

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22. okt 2025, 10:31 UTC

Tulu

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22. okt 2025, 10:31 UTC

Tulu

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific 3Q Adj EPS 75c >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific 3Q Sales $5.07B >BSX

22. okt 2025, 10:30 UTC

Tulu

Boston Scientific 3Q EPS 51c >BSX

Võrdlus sarnastega

Hinnamuutus

Boston Scientific Corp. Prognoos

Hinnasiht

By TipRanks

42.82% tõus

12 kuu keskmine prognoos

Keskmine 125.78 USD  42.82%

Kõrge 140 USD

Madal 112 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Boston Scientific Corp. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

20

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

102.95 / 104.93Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

298 / 361 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat